EZH2 and breast cancer: This is the case, for example, of EZH2 (responsible for H3K27 trimethylation), frequently overexpressed in aggressive BC subtypes and correlated with tumor proliferation, EMT, metastatic potential and poor prognosis [139,140], and of SUV4-20H2 (responsible for H4K20 methylation), whose expression is conversely reduced in BC and associated with invasive activity [120].